Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib

    December 2023 in “ Journal of clinical medicine ”
    Francesca Ambrogio, Melita Anna Poli, Lucia Lospalluti … Caterina Foti
    Studysummary This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case Indian Journal of Pharmacology · 2021
    2. Nilotinib Induced Keratosis Pilaris Atrophicans Dermatology Online Journal · 2016
    3. Nilotinib-Induced Keratosis Pilaris Case Reports in Dermatology · 2016
    4. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia Dermatology · 2015
    5. Ponatinib‐induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities British Journal of Dermatology · 2015
    6. Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia Journal of the American Academy of Dermatology · 2013
    7. Correction: RASopathic Skin Eruptions During Vemurafenib Therapy PLoS ONE · 2013
    8. RASopathic Skin Eruptions During Vemurafenib Therapy PLoS ONE · 2013